Redhill Biopharma Ltd. current report, Q2 FY2013

Redhill Biopharma Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, for the month of June 2013. The filing serves to distribute a notice, proxy statement, and proxy card to shareholders regarding the upcoming Annual General Meeting of Shareholders.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing related to corporate governance and does not contain financial statements or performance data.

Material Changes

No material changes to financial performance or operations are reported in this filing. The document focuses solely on the administrative process for the Annual General Meeting.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is limited to the notification of the shareholder meeting materials.

Key Facts for Investors

  • The company is convening an Annual General Meeting of Shareholders.
  • Shareholders will receive a notice, proxy statement, and proxy card.
  • The report was signed by Dror Ben-Asher, Chief Executive Officer, on June 26, 2013.
  • No financial data is included in this specific filing.